DeSilva Nishan M
Known title: DirectorCIK: 0001492386
DeSilva Nishan M's purchase track record
DeSilva Nishan M has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/2/2021 | RNAC | $21K | -43.1% | -73.0% | -8.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RNAC | ▲ Buy | Grant | 2,600 | $0 | 1/2/2026 | View on chart |
| RNAC | ▲ Buy | Grant | 2,600 | $0 | 1/2/2025 | View on chart |
| RNAC | ▲ Buy | Grant | 178,000 | $0 | 1/2/2024 | View on chart |
| RNAC | ▲ Buy | Open Market | 7,000 | $21K | 12/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session
Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session. Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.